Application of Liposomes in Non-Viral Vectors
DOI:
https://doi.org/10.54097/wgxz5v35Keywords:
Gene delivery, non-viral vectors, LNPs, Ionizable lipid.Abstract
With the development of pathology, the traditional way of drug delivery is gradually unable to meet the needs of increasingly complex cancers, genetic diseases, and other drug delivery needs, so gene delivery was born. Precise, efficient delivery reduces damage to normal cells, improves treatment effect, and reduces the amount of drug used, hence the growing academic interest in gene delivery. To design more efficient and less harmful delivery vectors, non-viral vectors are gradually replacing the traditional viral vectors. As the most advanced non-viral vectors, lipid nanoparticles (LNPs) are widely used, such as Pfizer's COVID-19 vaccine —— a vaccine with a prevention efficacy of up to 75% was designed within a short research and development cycle. This article will summarize the existing information on LNPs as non-viral vectors, including delivery processes, target recognition, existing drawbacks, etc., to find vector designs with higher delivery efficiency, lower toxicity, and more generalizability.
Downloads
References
Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery systems. Pharmaceut Med. 2011, 25(5): 293-306.
Yin H., Kanasty, R., Eltoukhy A. et al. Non-viral vectors for gene-based therapy. Nature Reviews Genetics, 2014, 15: 541-555.
Wahane A., Waghmode A., Kapphahn A., et al. Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. Molecules, 2020, 25: 2866.
Han X., Zhang H., Butowska K., et al. An ionizable lipid toolbox for RNA delivery. Nature Communications, 2021, 12: 7233.
Suzuki T., Suzuki Y., Hihara T., et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. International Journal of Pharmaceutics, 2020, 588: 119792.
Lin J.C., Tam Y.Y.C., Hafez I., et al. Influence of cationic lipid composition on the uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine: Nanotechnology, Biology and Medicine, 2013, 9(2): 233-246.
Semple S.C., Akinc A., Chen J., et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 2010, 28(2): 172-176.
Gardlík R., Pálffy R., Hodosy J., et al. Vectors and delivery systems in gene therapy. Medical Science Monitor, 2005, 11(4): 110-121.
Katare D.P., Aeri V. Progress in gene therapy: a review. IJTPR, 2010, 1(33): e41.
Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383(27): 2603-2615.
Soutschek J., Akinc A., Bramlage B., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432: 173.
Gyanani V., Goswami R. Key design features of lipid nanoparticles and electrostatic charge-based lipid nanoparticle targeting. Pharmaceutics, 2023, 15(4): 1184.
Dilliard S.A., Cheng Q., Siegwart D.J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles [Medical Sciences]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118: e2109256118.
Eygeris Y., Gupta M., Kim J., et al. Chemistry of lipid nanoparticles for RNA delivery. Accounts of Chemical Research, 2021, 55(1): 2-12.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
